Gilead Buys Pipeline-In-A-Product With $21bn Immunomedics Deal
Acquisition Gives The Big Biotech Its First Approved Solid Tumor Drug
The company paid twice Immunomedics’ last closing stock price to access Trodelvy, approved for triple-negative breast cancer with potential in other solid tumors as monotherapy and in combinations.
You may also be interested in...
The US firm gets development and co-commercial rights to MORAb-202 for $650m up front. BMS joins AstraZeneca, Merck & Co. and Gilead in recent ADC deal-making.
The company previously was unsuccessful securing accelerated approval based on complete response data, but event-free survival results may be more persuasive.
Tezepelumab was among four products that the European Medicines Agency most recently considered for review under its accelerated assessment mechanism.